{
  "claim_id": "claim_005",
  "claim": "Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
  "document": "Liu_et_al.__2024_",
  "additional_evidence_check": {
    "checked_for_more": true,
    "found_additional": true,
    "additional_count": 5
  },
  "completeness_stats": {
    "existing_evidence": 5,
    "new_evidence_found": 5,
    "total_evidence": 8
  },
  "combined_evidence": [
    {
      "id": 1,
      "quote": "In this randomized trial (Clinical trials gov: NCT03722589), sera pre- and post vaccination with quadrivalent inactivated egg based (IIV4), cell culture based (ccIIV4), and recombinant (RIV4) influenza",
      "relevance_explanation": "This quote explicitly states that the trial evaluated quadrivalent recombinant influenza vaccine (RIV4, which is Flublok) alongside quadrivalent inactivated egg-based (IIV4) and cell culture-based (ccIIV4) vaccines, confirming that Flublok (quadrivalent) was evaluated in the pivotal trial."
    },
    {
      "id": 2,
      "quote": "Enrolled and Randomized n=723 vaccine Allocation Flu zone IIV4 n=122 18-44 years: n=57 45-64 years: n=65 Completed day 0 (n=110) 1 month (n=110) and 6 months (n=101) visit Fluarix IIV4 n=120 18-44 years: n=55 45-64 years: n=65 Completed day 0 (n=120) 1 month (n=118) and 6 months (n=107) visit ... RIV4 in Year 1 n=152",
      "relevance_explanation": "This quote lists the randomized allocation of participants to Fluarix IIV4 (a quadrivalent standard-dose vaccine) and RIV4 (Flublok quadrivalent), directly supporting that Flublok was evaluated against Fluarix in the pivotal trial."
    },
    {
      "id": 3,
      "quote": "sera pre- and post vaccination with quadrivalent inactivated egg based (IIV4), cell culture based (ccIIV4), and recombinant (RIV4) influenza",
      "relevance_explanation": "This quote confirms that the study compared the recombinant quadrivalent vaccine (Flublok) with quadrivalent inactivated vaccines, which include Fluarix, thus directly supporting the claim."
    },
    {
      "id": 4,
      "quote": "Fluarix IIV4: Day 0 (n = 24), 1 m (n = 24), 6 m (n = 23); ccIIV4: Day 0 (n = 56), 1 m (n = 54), 6 m (n = 51); RIV4: Day 0 (n = 40), 1 m (n = 40), 6 m (n = 38).",
      "relevance_explanation": "This quote provides explicit evidence that Flublok (RIV4) and Fluarix (IIV4) were both evaluated in the same trial, with participant numbers given for each group."
    },
    {
      "id": 5,
      "quote": "Fluarix IIV4 18\u221244 years: Day 0 (n = 55), 1 m (n = 55), 6 m (n = 48); ... RIV4 18\u221244 years: Day 0 (n = 99), 1 m (n = 98), 6 m (n = 85); RIV4 45\u221264 years: Day 0 (n = 98), 1 m (n = 98), 6 m (n = 92);",
      "relevance_explanation": "This quote shows that both Fluarix (quadrivalent standard-dose) and Flublok (quadrivalent recombinant) were administered to participants in the pivotal trial, supporting the claim."
    },
    {
      "id": "comp_1",
      "quote": "acell culture based influenza vaccine (Flucelvax Quadrivalent by Seqirus, Inc., ccIIV4) and a recombinant influenza vaccine (Flublok Quadrivalent by Sanofi Pasteur, RIV4). RIV4 contains 3 times the i d 45 HA/d / ...d",
      "relevance_explanation": "This quote explicitly identifies Flublok Quadrivalent (RIV4) as the recombinant influenza vaccine evaluated in the trial, and distinguishes it from the cell culture-based vaccine, supporting the claim that Flublok was one of the vaccines tested in the pivotal trial.",
      "source": "completeness_check",
      "metadata": {
        "extraction_round": 2,
        "targeted_aspect": "general"
      }
    },
    {
      "id": "comp_2",
      "quote": "Enrolled and Randomized n=723 vaccine Allocation Flu zone IIV4 n=122 18-44 years: n=57 45-64 years: n=65 Completed day 0 (n=110) 1 month (n=110) and 6 months (n=101) visit Fluarix IIV4 n=120 18-44 years: n=55 45-64 years: n=65 Completed day 0 (n=120) 1 month (n=118) and 6 months (n=107) visit e-enrolled in Year 2 and new enroll ees randomized n=684 (139*) ccIIV4 in Year 1 n=214 RIV4 in Year 1 n=152",
      "relevance_explanation": "This quote lists the vaccine allocation for the randomized participants, showing that both Fluarix IIV4 (a quadrivalent standard-dose vaccine) and RIV4 (Flublok Quadrivalent) were used in the trial, directly supporting the claim.",
      "source": "completeness_check",
      "metadata": {
        "extraction_round": 2,
        "targeted_aspect": "general"
      }
    },
    {
      "id": "comp_5",
      "quote": "Day 0 1 m 6 mccIIV4 45\u221264 years: Day 0 (n = 148), 1 m (n = 147), 6 m (n = 142); RIV4 18\u221244 years: Day 0 (n = 99), 1 m (n = 98), 6 m (n = 85); RIV4 45\u221264 years: Day 0 (n = 98), 1 m (n = 98), 6 m (n = 92); Micro neutralization titers (MN) were measured for A (H3 N2) virus, while hem agglutination inhibition (HI) titers were measured for A (H1 N1) pdm09, B/Victoria (B/VIC), and B/Yamagata (B/YAM) viruses. One way ANOVA corrected for multiple comparisons (Tukey'stest) was used to compare the GMTs of each time point among the 4 vaccine groups. Statistically significant differences",
      "relevance_explanation": "This quote shows that RIV4 (Flublok Quadrivalent) and Fluarix IIV4 were both included as vaccine groups in the trial, and their immunogenicity was compared using statistical analysis, directly supporting the claim.",
      "source": "completeness_check",
      "metadata": {
        "extraction_round": 2,
        "targeted_aspect": "general"
      }
    }
  ],
  "completeness_assessment": {
    "missing_aspects": []
  },
  "model_used": "gpt-4.1"
}